Real-world evaluation of costs of illness for pneumonia in adult patients in Dubai-A claims database study.

Sara Ahmad Mohammad Al Dallal, Mohamed Farghaly, Ahmed Ghorab, Mostafa Elaassar, Hammam Haridy, Nancy Awad, Badarinath Chickballapur Ramachandrachar, Ashok Natarajan
Author Information
  1. Sara Ahmad Mohammad Al Dallal: Health Economics & Insurance Policies Department, Dubai Health Authority, Dubai, UAE. ORCID
  2. Mohamed Farghaly: Health Economics & Insurance Policies Department, Dubai Health Authority, Dubai, UAE.
  3. Ahmed Ghorab: Health & Value and Patient Outcomes, Pfizer, Dubai, UAE.
  4. Mostafa Elaassar: Vaccines, Medical & Scientific Affairs, Pfizer, Dubai, UAE.
  5. Hammam Haridy: Vaccines, Medical & Scientific Affairs, Pfizer, Dubai, UAE.
  6. Nancy Awad: Real World Evidence, IQVIA, Dubai, UAE.
  7. Badarinath Chickballapur Ramachandrachar: Real World Evidence, IQVIA, Dubai, UAE.
  8. Ashok Natarajan: Real World Evidence, IQVIA, Dubai, UAE.

Abstract

BACKGROUND: Pneumonia is a significant cause of morbidity and mortality among adults globally. This retrospective cohort analysis assessed the pneumonia burden and related healthcare resource utilization and costs in the at-risk (low, medium, and high-risk) adult patients in Dubai, United Arab Emirates (UAE).
METHODS: The claims data from January 1, 2014 to June 30, 2019 were extracted from the Dubai Real-World Claims Database for patients, aged ≥18 year, having at least 1 pneumonia claim. Data for the inpatient, outpatient and emergency visits were assessed for 12-months, before (pre-index) and after (follow-up) a pneumonia episode. Healthcare costs were calculated based on dollar value of 2020.
RESULTS: Total 48,562 records of eligible patients were analyzed (mean age = 39.9 years; low [62.1%], medium [36.2%] and high [1.7%] risk cohorts). Mean all-cause healthcare costs were approximately >45% higher in the follow-up period (1,947 USD/patient) versus pre-index period (1,327 USD/patient). During follow-up period, the mean annual pneumonia incidence rate was 1.3 episodes, with a similar pattern across all cohorts. Overall, mean claims and costs (USD) per patient (all-cause) were highest in the high-risk cohort in the follow-up period (claims: overall, 11.6; high-risk, 22.0; medium-risk, 13.9; low-risk, 9.9; costs: high-risk, 14,184; medium-risk, 2,240; low-risk, 1,388). Similarly, the mean pneumonia-related costs (USD) per patient were highest for the high-risk cohort (overall: 1,305; high-risk, 10,207; medium-risk, 1,283; low-risk, 882), however, the claims were similar across cohorts (claims/patient: overall: 2.0; high-risk, 1.9; medium-risk, 2.2; low-risk, 1.9). Most all-cause and pneumonia-related costs were due to inpatient visits (4,901 and 4,818 USD respectively), while outpatient (1,232 and 166 USD respectively) and emergency visits (347 and 206 USD respectively) contributed significantly lesser.
CONCLUSIONS: Pneumonia imposes a significant healthcare burden in the UAE, especially in the high-risk patients with severe comorbidities. These findings would guide clinicians and policy makers to make informed decisions.

References

  1. Hum Vaccin Immunother. 2017 Jul 3;13(7):1673-1680 [PMID: 28281915]
  2. Int J Antimicrob Agents. 2002;20 Suppl 1:S1-12 [PMID: 12445763]
  3. Thorax. 2012 Jan;67(1):71-9 [PMID: 20729232]
  4. Lancet Glob Health. 2018 Jul;6(7):e744-e757 [PMID: 29903376]
  5. PLoS One. 2017 Apr 6;12(4):e0175224 [PMID: 28384325]
  6. PLoS One. 2013 Oct 09;8(10):e75887 [PMID: 24130749]
  7. Monaldi Arch Chest Dis. 2006 Mar;65(1):13-8 [PMID: 16700188]
  8. Clin Infect Dis. 2016 Jan 15;62(2):139-47 [PMID: 26354970]
  9. Lancet Infect Dis. 2018 Nov;18(11):1191-1210 [PMID: 30243584]
  10. Lancet. 2011 Apr 9;377(9773):1264-75 [PMID: 21435708]
  11. Am Fam Physician. 2016 Nov 1;94(9):698-706 [PMID: 27929242]
  12. East Mediterr Health J. 2016 Oct 02;22(7):513-526 [PMID: 27714746]
  13. Am Health Drug Benefits. 2013 Sep;6(8):494-503 [PMID: 24991378]
  14. J Med Virol. 2019 Aug;91(8):1378-1384 [PMID: 30900750]
  15. Bull World Health Organ. 2008 Oct;86(10):A; author reply A-C [PMID: 18949200]
  16. Int J Clin Exp Med. 2015 Aug 15;8(8):12463-75 [PMID: 26550157]
  17. J Clin Invest. 2008 Apr;118(4):1291-300 [PMID: 18382741]
  18. Clin Epidemiol. 2017 Jun 02;9:311-320 [PMID: 28652813]
  19. J Chronic Dis. 1987;40(5):373-83 [PMID: 3558716]
  20. Clin Infect Dis. 2001 Sep 1;33(5):662-75 [PMID: 11486289]
  21. Pneumonia (Nathan). 2017 Dec 5;9:19 [PMID: 29226070]
  22. Medicine (Baltimore). 2017 Nov;96(44):e8429 [PMID: 29095281]
  23. Eur J Vasc Endovasc Surg. 2018 Nov;56(5):615-616 [PMID: 29960853]
  24. Chest. 2007 Apr;131(4):1205-15 [PMID: 17426229]
  25. J Infect Public Health. 2013 Dec;6(6):401-9 [PMID: 23999349]

MeSH Term

Administrative Claims, Healthcare
Adolescent
Adult
Cost of Illness
Databases, Factual
Female
Follow-Up Studies
Health Care Costs
Humans
Male
Middle Aged
Patient Acceptance of Health Care
Pneumonia
Retrospective Studies
United Arab Emirates
Young Adult

Word Cloud

Created with Highcharts 10.0.01high-riskcosts9pneumoniapatientsUSDclaimsfollow-upmeanperiodmedium-risklow-risk2cohorthealthcarevisitscohortsall-causerespectivelyPneumoniasignificantassessedburdenlowmediumadultDubaiUAEinpatientoutpatientemergencypre-indexUSD/patientsimilaracrossperpatienthighest0pneumonia-relatedoverall:4BACKGROUND:causemorbiditymortalityamongadultsgloballyretrospectiveanalysisrelatedresourceutilizationat-riskUnitedArabEmiratesMETHODS:dataJanuary2014June302019extractedReal-WorldClaimsDatabaseaged≥18yearleastclaimData12-monthsepisodeHealthcarecalculatedbaseddollarvalue2020RESULTS:Total48562recordseligibleanalyzedage=39years[621%][362%]high[17%]riskMeanapproximately>45%higher947versus327annualincidencerate3episodespatternOverallclaims:overall1162213costs:14184240388Similarly30510207283882howeverclaims/patient:due901818232166347206contributedsignificantlylesserCONCLUSIONS:imposesespeciallyseverecomorbiditiesfindingsguideclinicianspolicymakersmakeinformeddecisionsReal-worldevaluationillnessDubai-Adatabasestudy

Similar Articles

Cited By